09637 禮邦醫藥－Ｂ
ALEBUND-B
ALEBUND-B
| Register Close | 2026/06/24 IPO Closing in 6 Days |
| Listing Date | 2026/06/29 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Alebund Pharmaceuticals (Jiangsu) Ltd. was founded in 2018, it is a biopharmaceutical company providing renal therapies.
--
The Group’s product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate (AP306), one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307) as of June 12, 2026.
--
The Group’s sole Core Product, AP301 is classified as a Class 1 new chemical drug in China and it is a phosphate binder for the treatment of hyperphosphatemia. AP306 is a differentiated pan-phosphate transporter inhibitor for hyperphosphatemia in CKD patients receiving dialysis.
--
As of June 12, 2026, the Group held 153 patents and patent applications, among which 24 were related to its Core Product. The Group has completed the construction of an in-house manufacturing facility in Yangzhou, China, and its revenue was generated from a single customer, which is its distributor for Mircera in China.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 56.76M H shares |
| No. of International Offer Shares | 51.08M H shares |
| No. of HK Offer Shares | 5.68M H shares |
| Offer Price | $22.60 |
| Stock Code | 9637 |
| Sponsor(s) | Jefferies Hong Kong Limited, Merrill Lynch (Asia Pacific) Limited, Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | Jefferies Hong Kong Limited, Merrill Lynch (Asia Pacific) Limited, Huatai Financial Holdings (Hong Kong) Limited, CLSA Limited, BOCI Asia Limited |
TIME TABLE
| Application Period | Jun 18 (Thu) - noon, Jun 24 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 26 (Fri) |
| Result Announcement Date | On or before Jun 26 (Fri) |
| Result Announcement Date | On or before Jun 29 (Mon) |
| Dealings in Shares commence on | Jun 29, 2026. (Mon) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $22.60 |
| Capitalization (H Shares) | 5.13B |
| NAV / share ($) | $5.21 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 22.6, the net proceeds raised would be HKD 1.18B, of which |
| 71% : AP301 evolving business needs and changing market conditions |
| 7% : Other product candidates evolving business needs |
| 12% : Commercialization of drug candidates after approved for sale |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).